Patents by Inventor Soile Tuomela

Soile Tuomela has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INTERLEUKIN 32 AS A BIOMARKER OF TYPE 1 DIABETES
    Publication number: 20200264192
    Abstract: The present invention relates to interleukin 32 (IL-32) as a predictive marker of Type 1 diabetes (T1D). The invention also relates to a method of predicting an individual's risk of or progression towards T1D, and to a kit for use in said method.
    Type: Application
    Filed: September 27, 2018
    Publication date: August 20, 2020
    Applicant: TURUN YLIOPISTO
    Inventors: Juhi SOMANI, Soile TUOMELA, Henna KALLIONPÄÄ, Riitta LAHESMAA, Harri LÄHDESMÄKI, Riikka LUND, Mikael KNIP
  • Method of Predicting Risk for Type 1 Diabetes
    Publication number: 20190136322
    Abstract: The present invention relates to methods, transcriptome profiles and kits useful for determining, before seroconversion, the risk that an individual will develop Type 1 diabetes (T1D).
    Type: Application
    Filed: December 21, 2018
    Publication date: May 9, 2019
    Inventors: Henna Kallionpaa, Laura L. Elo, Essi Laajala, Juha Mykkanen, Olli Simell, Riitta Lahesmaa, Harri Lahdesmaki, Lingjia Kong, Soile Tuomela, Niina Lietzen
  • Method of Predicting Risk for Type 1 Diabetes
    Publication number: 20160145687
    Abstract: The present invention relates to methods, transcriptome profiles and kits useful for determining, before seroconversion, the risk that an individual will develop Type 1 diabetes (T1D).
    Type: Application
    Filed: June 25, 2014
    Publication date: May 26, 2016
    Inventors: Henna Kallionpaa, Laura L. Elo, Essi Laajala, Juha Mykkanen, Olli Simell, Riitta Lahesmaa, Harri Lahdesmaki, Lingjia Kong, Soile Tuomela, Niina Lietzen
  • Methods and means related to diseases
    Patent number: 8143029
    Abstract: The present invention relates to the fields of genetics and oncology and provides methods for detecting cutaneous T-cell lymphomas (CTCL) or susceptibility to CTCL. Specifically, the present invention relates to a novel method for the diagnosis and follow-up of CTCL or CTCL subtype, the method comprising determination of expression of one or more genes, gene fragments or gene products. The present invention further relates to a novel method of detecting the response to CTCL therapy, the method comprising determining expression of one or more genes or gene fragments or gene products in a biological sample. The present invention further relates to a novel method of developing or improving CTCL therapy or developing anti-CTCL medicament, the method comprising screening agents affecting one or several of the genes or gene products. The present invention further relates to a novel method of treating CTCL patients, the method comprising affecting one or several of the genes or gene products.
    Type: Grant
    Filed: December 21, 2006
    Date of Patent: March 27, 2012
    Assignee: Valipharma
    Inventors: Annamari Ranki, Sonja Hahtola, Leena Karenko, Soile Tuomela, Riitta Lahesmaa, Kai J. E Krohn
  • Methods and Means Related to Diseases
    Publication number: 20100035971
    Abstract: The present invention relates to the fields of genetics and oncology and provides methods for detecting cutaneous T-cell lymphomas (CTCL) or susceptibility to CTCL. Specifically, the present invention relates to a novel method for the diagnosis and follow-up of CTCL or CTCL subtype, the method comprising determination of expression of one or more genes, gene fragments or gene products. The present invention further relates to a novel method of detecting the response to CTCL therapy, the method comprising determining expression of one or more genes or gene fragments or gene products in a biological sample. The present invention further relates to a novel method of developing or improving CTCL therapy or developing anti-CTCL medicament, the method comprising screening agents affecting one or several of the genes or gene products. The present invention further relates to a novel method of treating CTCL patients, the method comprising affecting one or several of the genes or gene products.
    Type: Application
    Filed: December 21, 2006
    Publication date: February 11, 2010
    Inventors: Annamari Ranki, Sonja Hahtola, Leena Karenko, Soile Tuomela, Riitta Lahesmaa, Kai J.E. Krohn